NICE backs expanded use of AbbVie's Ozurdex

12 August 2022

The UK unit of US pharma major AbbVie (NYSE: ABBV) says that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document recommending Ozudrex (dexamethasone intravitreal implant) as a treatment option within the National Health Service (NHS), for adults with visual impairment caused by diabetic macular edema (DMO), when their condition has not responded well enough to, or they cannot have non-corticosteroid therapy.

Until now, use of dexamethasone intravitreal implant within the NHS has only been available to these patients if they had an artificial (pseudophakic) lens. This recommendation from NICE extends use of the implant to include those with a natural (phakic) lens and means that suitable DMO patients will now have access to an additional treatment option beyond non-cortiocosteroid therapy.1

DMO is a complication of diabetes which affects approximately 7% of 3.5 million people with the condition in England. It is one of the leading causes of preventable sight loss in the UK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK